

## Review

## Open Access

# HIV prevention cost-effectiveness: a systematic review

*f* G B A C **b** \*<sup>1</sup>, **b** G <sup>3</sup> **n**

**Background**

Af h n 25 n n f  
n n ff ' h h h HI  
n f n n h AID HI -  
n 2007 1 ; 7,000 n f h HI  
f f 2 . n n f h n h -

n b b n n 1 f b f CE  
 506 f n A n n f 90 n f b n  
 f f - n .  
 b b b f CEA f - n : b n f b n n f b f  
 n b n n n ( n - n n n f )  
 f n n n ( b , )  
 b f n n n n n . B n  
 b , 21 n CE .  
 b n f n b f b f b f f n  
 b b . n b f b n f b n n n ,  
 b b f n , n b n n ,  
 ( n n , n b n b b ) n b n CE .  
 CE (HIA) DAL / AL HI n f n  
 b n .  
 b f n f n b n b AID n b  
 H b n n n ( H ) 9 n n n  
 HI n n b n b Lancet 10,12-14 . -  
 b f b n n n f n  
 n b n n f n n n n  
 n b f f f CE f f n n n n f n .  
 A b f f n 15 , f n .

), f i A ( f - L n A ( n n n -  
 ) n n n f E n E ( n n n -  
 ). b 23  
 b n . A n F 1.

b b n f b n , b f n -  
 n f n n .

**Behavior change interventions**

b f HI n f n b n n f n f b  
 n - b 14 . f n n  
 b n f n n n ( C ), n b -

A n C v n , b Af 20 , b  
 n CE f b E , n  
 HI n n b b n n n -  
 n ( C ). b b n n -  
 f n n n - b HI n f n  
 (HIA) n b B n . b -  
 HIA C n E \$ 67 n b  
 I n n \$ 112 n b b 9(0) 199999( ( 8( 6.1 ( F 1.) 86E B .0927 1.20990002 L9.72000026 0 0 9.72

**6A7 Di VJMKYUR** 00 , 9( 1)

// . . / 1 1- / / 1/

, b 1,000 C 308 HI m f -  
 n n n \$2.4 f . A n b  
 HI , b b b b C , b - f  
 b n n n .

An b n f b n , f C n  
 HI n b , m f n n f 34 b  
 f f (40-60%) n n (25-  
 100%). b b HIA n n \$ 1,269  
 n \$ 3,911 75% , b f n C  
 - f n b b f \$ 69 -  
 n .

n , B n n n L b  
 n . B n 35,37 C n CE -  
 n b n - b n - n n  
 n f n C 15-49 n -  
 f 52.5% (L b ) n 57.5% ( n )  
 n b n (2008-2020). CE  
 n b HIA n n f HIA -  
 n . b CE f n \$ 292 n L b  
 n \$ 176 n n n HI m f n  
 f 6.1 n 4.1 n ,  
 n L b n n . I n b b CE n -  
 n n n b n b f n b  
 b b C b b - f b  
 n n .

An n - f b b f  
 b n Af b b - HI - n ( n 2007 n n -  
 \$ ) HIA

**6A7 Di VJMKYUR**



n            b            b            f C  
 n n            ,            n n            n f  
 n            54 .            b ,            f n            n  
 C 55 b f HI            n n f n n n :  
 n , n n n b            n . b            f b b  
 n b n n n HI            HI - n n  
 n b n . F            HI - n n  
 , b n            n n  
 ( \$ 17) b n b            ( \$ 24) n b            n  
 ( \$ 38) . H            , b            n  
 n            HIA            n n n b  
 n .

**Biomedical interventions**

I n n b n f CE n  
 b n b n b f b n b 56-  
 58 . , n f HI b n  
 59 . A n n n n n n  
 n b f n n n b b -  
 n ff n n n 60,61 n b  
 b HI  
 62,63 . f , b n n n  
 b III ff b n ff 64 . F -  
 b , n n b n b n  
 n f n n 65 b b n -  
 n 63 . b , n b b n  
 n n \$ 800 n  
 66 , n n n ff 67 . -  
 n b n n n n n b  
 n f n n n ; b , b -  
 n ff n n n n n  
 ff n 68 .

F b , b n n n B n n  
 69 b b b b , n ff n b CE n -  
 . b , b b b b CE  
 n ; , n n ,  
 n ff n n b b b b f b  
 b CE f n .

n n 24  
 n A n n , b b ff -  
 n n 70-73 . A ,  
 n b n n , n n -  
 n n . H n , b n  
 b n A n n n n ff  
 b n b .0999999( )-6( n A n )-6.199999( )-CE n 9999( )-1( n  
 790

b b b n . F C b n n  
 D 84 n f K n b n -  
 n n n -  
 n n n -  
 n n ) -  
 n b b b n b HI -  
 n n n f n . b b b b  
 b b n n ( ) n b  
 n f n H , b n f f n  
 n f HI - b .

85 , b n b n b n ( -  
 f n b f b ) n n b n ( -  
 ( b 39% f n b n f HI 80%  
 b n n n ). F b , HI - -  
 n b n b n f n b  
 n f n b , n f n  
 b n n n 85 .

A b b f HI n f -  
 n (HIA), b n n f n , -  
 n f 86 n b n n b  
 b n n n HI . n

**6A7 Di VJMKYUH** 00 , 9( 1)

// . . . / 1 1- / / 1/

**6A7 Di VJMKYUR 00 , 9**

**6A7 Di VJMKYUR 00 , 9**

